Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENO-01 in extra-nodal MALT lymphoma
2012-001768-31Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Aug 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in extranodal marginal zone B-cell lymphoma (EMZL) and Gastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissue, sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Overall response rate. Started Aug 2012; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)Gastric Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissue
Beyond the preview
Go deeper on 2012-001768-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001768-31.